Pulmonary Hypertension

ClinicalJune 29, 2026

Trial on Vasopressor Agents for Pulmonary Hypertension Crisis Initiated

A prospective, randomized controlled trial is underway to compare the efficacy and safety of dopamine, norepinephrine, and epinephrine in treating pulmonary hypertension crisis.

Companies

Assets

Recent signals(12)

Study on Aerobic Exercise Benefits for Pulmonary Hypertension Patients

FDA Grants Approval for ILOPROST ANDA214997 by BELOTECA

FDA Accepts Supplement Application for RIOCIGUAT by MSN

FDA Accepts Supplement for ADEMPAS (Riociguat) by Bayer Healthcare

United Therapeutics' Ralinepag Shows Potential in Improving Exercise Capacity in PH Patients

Study on Endothelial Cell Dysfunction in Pulmonary Hypertension Launched by NIH

FDA Approval Status Update for Bosentan ANDA207760 by Zydus Pharmaceuticals

Trial on Vasopressor Agents for Pulmonary Hypertension Crisis Initiated

Study on Risk Factors for Acute Pulmonary Hypertension Crisis Launched

Eko Devices Initiates Study on Detecting Pulmonary Hypertension with Electronic Stethoscope

Establishment of Pulmonary Hypertension Biorepository for Future Biomarker Discovery

Phase 3 Study of L606 in Patients with PH-ILD Shows Safety and Efficacy Potential

Upcoming catalysts

Indications

Get signals before the market moves